biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier ...
VANCOUVER, BC--(Marketwired - August 29, 2016) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), …